127 related articles for article (PubMed ID: 37672016)
21. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
[TBL] [Abstract][Full Text] [Related]
22. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.
Kane JM; Schooler NR; Marcy P; Correll CU; Achtyes ED; Gibbons RD; Robinson DG
JAMA Psychiatry; 2020 Dec; 77(12):1217-1224. PubMed ID: 32667636
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Li H; Luo J; Wang C; Xie S; Xu X; Wang X; Yu W; Gu N; Kane JM
Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
[TBL] [Abstract][Full Text] [Related]
25. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
Potkin SG; Preda A
Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
Ishigooka J; Noda T; Nishiyama K; Tamaru N; Shima T; Yamasaki Y; Tadori Y
Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Jun; 36(3):63-8. PubMed ID: 27506082
[TBL] [Abstract][Full Text] [Related]
27. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
[TBL] [Abstract][Full Text] [Related]
28. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
[TBL] [Abstract][Full Text] [Related]
29. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.
Kane JM; Sanchez R; Baker RA; Eramo A; Peters-Strickland T; Perry PP; Johnson BR; Tsai LF; Carson WH; McQuade RD; Fleischhacker WW
Clin Schizophr Relat Psychoses; 2015; 9(2):79-87. PubMed ID: 25711509
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
San L; Estrada G; Oudovenko N; Vieta E
BMC Psychiatry; 2017 Apr; 17(1):126. PubMed ID: 28376877
[TBL] [Abstract][Full Text] [Related]
31. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
[TBL] [Abstract][Full Text] [Related]
32. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
33. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.
Kane JM; Zhao C; Johnson BR; Baker RA; Eramo A; McQuade RD; Duca AR; Sanchez R; Peters-Strickland T
J Med Econ; 2015 Feb; 18(2):145-54. PubMed ID: 25347448
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.
Ishigooka J; Nakamura J; Fujii Y; Iwata N; Kishimoto T; Iyo M; Uchimura N; Nishimura R; Shimizu N;
Schizophr Res; 2015 Feb; 161(2-3):421-8. PubMed ID: 25556976
[TBL] [Abstract][Full Text] [Related]
35. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
37. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis.
De Hert M; Eramo A; Landsberg W; Kostic D; Tsai LF; Baker RA
Neuropsychiatr Dis Treat; 2015; 11():1299-306. PubMed ID: 26064048
[TBL] [Abstract][Full Text] [Related]
39. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
Chan HY; Lin WW; Lin SK; Hwang TJ; Su TP; Chiang SC; Hwu HG
J Clin Psychiatry; 2007 Jan; 68(1):29-36. PubMed ID: 17284127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
